0R1B.LSE Biogen Inc.

Healthcare Drug Manufacturers - General London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
2.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 0R1B.LSE undervalued?

Graham number

The Graham number of Biogen Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biogen Inc. fundamental analysis

No fundamental analysis for Biogen Inc. yet.

Biogen Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimuma…

Full company profile